A randomized, double-blind, multicenter study of visilizumab versus placebo in subjects with intravenous steroid-refractory ulcerative colitis previously responsive in a visilizumab study.

Trial Profile

A randomized, double-blind, multicenter study of visilizumab versus placebo in subjects with intravenous steroid-refractory ulcerative colitis previously responsive in a visilizumab study.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Visilizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Abbott Biotherapeutics Corp; PDL BioPharma
  • Most Recent Events

    • 09 Mar 2012 Actual patient number 25 added as reported by ClinicalTrials.gov.
    • 25 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top